Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 33.47% | -6.81% | -10.08% | -7.97% | 8.91% |
| Total Depreciation and Amortization | -11.49% | -8.44% | -2.92% | 14.72% | 12.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 117.30% | 126.94% | 1,055.22% | -42.58% | -462.50% |
| Change in Net Operating Assets | -162.50% | -184.86% | -71.84% | 106.83% | 1,078.09% |
| Cash from Operations | 10.17% | -28.96% | 3.23% | -7.29% | 25.36% |
| Capital Expenditure | -49.06% | -9.68% | -0.57% | -24.60% | 16.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 97.39% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 106.10% | 116.86% | -122.62% | -16.45% | 40.30% |
| Cash from Investing | 28.49% | 91.53% | -166.24% | -37.16% | 29.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 646.65% | 56.19% | 169.14% | 453.91% | -84.18% |
| Repurchase of Common Stock | 25.73% | -10.30% | 17.04% | 2.89% | 22.02% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.93% | -4.54% | -4.26% | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 59.58% | -8.54% | 26.35% | 31.30% | -13.23% |
| Foreign Exchange rate Adjustments | 225.00% | -175.00% | -250.00% | 57.14% | -150.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.33% | 53.17% | -125.35% | 27.95% | 495.10% |